Telix provides an update on Illuccix® Reimbursement and Launch

Telix Pharmaceuticals Limited (ASX: TLX) has provided update on the U.S. and Australian launch and reimbursement status for Illuccix®. Illuccix is the Company’s  lead product used for assessing patients with supposed prostate cancer metastasis. The Company confirmed that its Illuccix® has been approved Transitional Pass-Through Payment Status by the U.S. Centers for Medicare and Medicaid Services (CMS).

From 01 July 2022, CMS along with commercial health insurers will identify the Healthcare Common Procedure Coding System Level II code A9596 assigned to Illuccix for reimbursement. From the same date, Pass-Through will allow CMS to offer separate payments for the radiopharmaceutical as well as the PET-CT scan, when performed with Illuccix in the hospital outpatient setting.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au